Rapamycin (Sirolimus)

Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。

価格 在庫  
USD 88 あり
USD 340 あり
USD 385 あり
USD 844 あり
電話番号: + 81 3-5632-9610mail@cosmobio.co.jp

Rapamycin (Sirolimus) 化学構造
分子量: 914.18

高品質保証

文献中の引用(63)

カスタマーフィードバック(12)

MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット

mTOR

IC50

~0.1 nM [1]

In vitro試験 Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29 NWrNUlhGS3m2b4TvfIlkKEG|c3H5 MlL6NVAhdk1? M3\HUFczKGh? MoL1SG1UVw>? MlnlVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 Mli0NlQ6ODB6N{O=
HT-29 M4\qfGN6fG:2b4jpZ{BCe3OjeR?= Ml\lNVAhdk1? NIf4THI4OiCq MVzEUXNQ M{PzWXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MV2yOFkxODh5Mx?=
HT-29 NH;ZfFJEgXSxdH;4bYMhSXO|YYm= M1vpeFExKG6P M3f4PFczKGh? M{LkT2ROW09? MmjXVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> Mlu4NlQ6ODB6N{O=
PC3 NIXOR4lMcW6jc3WgRZN{[Xl? M3HUSlExOCCwTR?= MlHQNUBp MXrEUXNQ NGKwfmpRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> M{XwXlIyQTd6Nkiz
PC3 M1LIdGtqdmG|ZTDBd5NigQ>? NVXUTmJ6OTByIH7N NVfxbHFkOSCq NFvWWHpFVVOR MnexSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MkfCNlE6Pzh4OEO=
PC3 NI[3VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxMlUh|ryP MnS2NUBp MWPEUXNQ MX7JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1? NXHOc5lJOjF7N{i2PFM>
HEK293 MlTmSpVv[3Srb36gRZN{[Xl? NXLIW4xZOTByIH7N MkjhPEBp MlrmSG1UVw>? M1Ttd2lvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= NFy3PWszOTV|OUOwNS=>
BT-20 MUTLbY5ie2ViQYPzZZk> NEnDfXkzOCEQvF2= M33vTGROW09? MkjRSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? MYCyNVM2OzV3MR?=
U937 NGHoNpVCdnSrYnHjeIVzcWGuIFHzd4F6 M2TvfVUxKM7:TR?= NXziS2FUPDhiaB?= M3HDe2ROW09? MnPnTY5lfWOnczDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5Qhf2muZDD0fZBmKEynZ3nvcoVtdGFicH7leY1weGirbHGgVIhqdGGmZXzwbIliNTFiSmKzNkBqdiCXOUO3JINmdGy| NGK2No4zOTF2MkGwOi=>
U937 MVPBcpRq[mGldHXybYFtKEG|c3H5 MUO1NEDPxE1? M{HQXlQ5KGh? NFznT5NFVVOR NHHkXplFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| M3nhbVIyOTR{MUC2
U937 MV\BcpRq[mGldHXybYFtKEG|c3H5 Ml7hOVAh|ryP NIDzSGY1QCCq MoWwSG1UVw>? M{nHUmRw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ MV2yNVE1OjFyNh?=
MCF-7 NFLrPY9CfXSxcHjh[5khSXO|YYm= Mn7pN|Ahdk1? NWP0VWJ{PCCq MUHEUXNQ Mn2xTY5lfWOnczDheZRweGijZ4m= MnvJNlAxOjhzM{S=
U87MG MonvT4lv[XOnIFHzd4F6 NUjOVZNsOSEQvF2= M{foUVYhcA>? M2DqdmROW09? MWPQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>? MVmxPVg1QDRyNB?=
U87MG Mm\jT4lv[XOnIFHzd4F6 MYSxJO69VQ>? MlHmOkBp Mo\YSG1UVw>? MojKVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= MlTaNVk5PDh2MES=
U87MG NFfFTHpMcW6jc3WgRZN{[Xl? NWjiV41YOSEQvF2= M4HIeVYhcA>? M1y5e2ROW09? MnXVSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? M1[2[VE6QDR6NEC0
U87MG M2rOUWtqdmG|ZTDBd5NigQ>? NUDkWGRnOSEQvF2= Mlq0OkBp M374U2ROW09? NGHKSpNFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? NGjvRYQyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb M1;zbWF2fG:yaHHnfUBCe3OjeR?= NFfDc28xNjJizszN M1HBTVI1KGh? NHXNT45FVVOR M4\KWWlv\HWlZYOgZZV1d3CqYXf5 NXu2S|lxOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NFPKOI9CfXSxcHjh[5khSXO|YYm= MYiwMlIh|ryP Mn\FNlQhcA>? MYXEUXNQ NYC4SYNXUW6mdXPld{BifXSxcHjh[5k> NXr4b4VTOTh|OUG5OFk>
H4 MlzvSpVv[3Srb36gRZN{[Xl? MnrINE4zKM7:TR?= NHzLZ3gzPCCq NH;JbGVFVVOR MnzDTY5kemWjc3XzJJRp\SC{YYTpc{Bw\iCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNkB1dyCuaXfoeEBkcGGrbjCzJJN2[nWwaYSgNUBqdiCqdX3hckBJPCClZXzsdy=> NGfVbogyQDB{NEW4OC=>
HeLa Mof6SpVv[3Srb36gRZN{[Xl? NH:z[ZMyODBibl2= MlLJN|YhcA>? M{\GVGROW09? NIf3[2hKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MXuxO|U3OzN6NR?=
HeLa M3vtT2Z2dmO2aX;uJGF{e2G7 NEPPbWsyODBibl2= NH;FeVA{PiCq MWPEUXNQ MX;JcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MoDqNVc2PjN|OEW=
HeLa NV\wVlhNTnWwY4Tpc44hSXO|YYm= M1rjXlExOCCwTR?= NYDvblJOOzZiaB?= NYS5RopDTE2VTx?= MmroTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MV:xO|U3OzN6NR?=
SYF M2rVfmZ2dmO2aX;uJGF{e2G7 MWmxNFAhdk1? NXPUbG85OjRiaB?= NVjSb2FxTE2VTx?= M{izWGlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NXH3Z4hvOTd3NkOzPFU>
SYF NV7hV4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXteYYyODBibl2= NXXVUph4OjRiaB?= MkO3SG1UVw>? MmHFTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MoHoNVc2PjN|OEW=
HEK293T NF;6OnNCdnSrdnnyZYwhSXO|YYm= MorQNUBvVQ>? MVu0JIQ> M2PaeWROW09? NEXPfoRKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> M1n4OFE4PDh3NUCx
HEK293T MkH1RY51cX[rcnHsJGF{e2G7 MmHRNUBvVQ>? MUC0JIQ> M3\3eWROW09? NYDwVWtoUW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> M4DaWFE4PDh3NUCx
PBMC M4WwTGZ2dmO2aX;uJGF{e2G7 M2XCN|Ehdk1? MWexOEBl MWDEUXNQ MkP3VoVlfWOnczDDR3I2KGSnboPpeJk> NFPa[HoyPzR6NUWwNS=>
PBMC NGjX[ndHfW6ldHnvckBCe3OjeR?= MUmxJI5O NF;KSJYyPCCm NFXVWWpFVVOR MYHEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> MoXHNVc1QDV3MEG=
HEK293 cells NX7QRVdKU2mwYYPlJGF{e2G7 MkTwOVAhdk1? M3XTU|Q2KG2rbh?= NFTpO2dFVVOR M4PMb2lvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? MmXxNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NX:xS2duTnWwY4Tpc44hSXO|YYm= M37pW|ExOCCwTR?= NYDkNG5XPCCq NVzCUldUTE2VTx?= MX7JcoR2[2W|IHz1Z4ln\XKjc3WgdJJwfGWrbjD0doFvey2|cHzpZ4lv\yCrbjDEdo9{d3CqaXzhJI1mdGGwb3fhd5RmeiCVMjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKE5vbIXjJIFv\CCFLXz1Zy=> NXvkbGpuOTdzMkiyOlI>
Human mixed lymphocyte NXPHbpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:yPWg2KG6P NYrKZ5VyTE2VTx?= Mnr5TWM2OD1zLk[gcm0v M4rVVFE3OTh3OE[1
Lewis rat lymph node cells MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P5OFUh|ryP MUHEUXNQ NFHGenJKSzVyPUKuOkDPxE1? NXzrd|RmOTZzOEW4OlU>
cells from the thymus of normal BALB/c mice M3ns[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHtNVAhdk1? MVW3NkBp MoHmSG1UVw>? MlK3TY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?= NYLU[5RZOTByMkG5OFg>
MRK-nu-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImyVZdKSzVyPUCuPFQ2KHCP NGTN[VdUSU6JRWK=
OCUB-M NUjJdGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fSfGlEPTB;NT6yOEBxVQ>? MWfTRW5ITVJ?
SF539 M4K1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXRfZhKSzVyPUGxMlYheE1? NVK1dnJiW0GQR1XS
ES4 NXzJenc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJzLkWgdG0> MoLpV2FPT0WU
RL95-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFyNzDwUS=> MVXTRW5ITVJ?
LC-2-ad MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz2TWM2OD12MkOgdG0> MlPkV2FPT0WU
Daudi NHTZTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjSUZJrUUN3ME20N|QheE1? M4f5XHNCVkeHUh?=
NTERA-S-cl-D1 M3nJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfmTWM2OD12NEOgdG0> NIThWIFUSU6JRWK=
OS-RC-2 NFfQeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZ3MjDwUS=> NFjr[VhUSU6JRWK=
VA-ES-BJ M2j3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjiR2RxUUN3ME23NlMheE1? MlP2V2FPT0WU
GR-ST NXfCOGlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X6cGlEPTB;OES2JJBO NUnMdGY1W0GQR1XS
SW872 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHvb2ZKSzVyPUi0OkBxVQ>? NGnIOnZUSU6JRWK=
NOS-1 NHjhb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLVZoxKSzVyPUi3NUBxVQ>? Mo\QV2FPT0WU
MC116 M2[1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\YblF[UUN3ME25PFUheE1? M{jqTXNCVkeHUh?=
NCI-H1355 NGHHXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPvS21ZUUN3ME2xMlAyKG6P NVWwd4ppW0GQR1XS
RPMI-8226 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HDRWlEPTB;MT6xPUBvVQ>? NFzHdGFUSU6JRWK=
TE-15 M2K4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwM{[gcm0> NEfKeYJUSU6JRWK=
Ramos-2G6-4C10 NVvaU3c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrWfo1KSzVyPUGuOFYhdk1? M{L1bXNCVkeHUh?=
KU812 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzuUHZKSzVyPUKuNFEhdk1? MXrTRW5ITVJ?
EW-1 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrmVnZKSzVyPUKuNVchdk1? M2\ScHNCVkeHUh?=
KS-1 NF3BV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwNEWgcm0> MlvZV2FPT0WU
SK-LMS-1 M4nGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTBXVhjUUN3ME2yMlQ6KG6P MX\TRW5ITVJ?
TGBC1TKB NXP5b3ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJwNkmgcm0> NX3MOG9bW0GQR1XS
TE-6 M171S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnGNmJbUUN3ME2yMlc4KG6P M1G0SnNCVkeHUh?=
ETK-1 M3zRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm0RXVDUUN3ME2yMlgzKG6P NXnkOXk6W0GQR1XS
BE-13 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD1{Lkm5JI5O NH:wd4RUSU6JRWK=
A3-KAW MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHRXZFbUUN3ME2yMlk6KG6P NFf3[pBUSU6JRWK=
TE-10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;MTWM2OD1|LkOgcm0> NIjGT45USU6JRWK=
DOHH-2 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3obVRiUUN3ME2zMlM2KG6P NVP6[nBoW0GQR1XS
ES6 M32zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH0TWM2OD1|LkSzJI5O M4HaXXNCVkeHUh?=
OPM-2 NEe0T2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDzTWM2OD12LkG1JI5O MYrTRW5ITVJ?
SH-4 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ToXWlEPTB;ND6zOEBvVQ>? MYXTRW5ITVJ?
NB13 NHjkV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nTSWlEPTB;ND6zOkBvVQ>? MoTxV2FPT0WU
HUTU-80 M2rzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwNEKgcm0> MWLTRW5ITVJ?
CCRF-CEM NEXSNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LHZ2lEPTB;ND65OEBvVQ>? M4HkfnNCVkeHUh?=
TGBC24TKB NWfybVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nGeGlEPTB;NT61NUBvVQ>? NEPvd2NUSU6JRWK=
697 Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37QdGlEPTB;Nj6yPEBvVQ>? MlfIV2FPT0WU
J-RT3-T3-5 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fme2lEPTB;Nj60OkBvVQ>? NYPsPYlWW0GQR1XS
KALS-1 NX7Qbm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZwNU[gcm0> M1;yOXNCVkeHUh?=
no-10 NFru[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTdwMkmgcm0> MXnTRW5ITVJ?
SK-NEP-1 NX3mZXZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1OGkzUUN3ME24Mlc6KG6P NEnjNXRUSU6JRWK=
L-540 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13nbGlEPTB;MUCuOFIhdk1? NIG1fotUSU6JRWK=
JiyoyeP-2003 NYT0NXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILKWZhKSzVyPUGwMlk1KG6P MYHTRW5ITVJ?
HH MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFzLkO5JI5O MlXYV2FPT0WU
SR NHnPd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;SO4Y1UUN3ME2xNU41PSCwTR?= NXrFOlVPW0GQR1XS
QIMR-WIL NEHme3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILjWnRKSzVyPUGxMlg2KG6P MnKzV2FPT0WU
A4-Fuk Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLI[VFjUUN3ME2xN{4yOiCwTR?= NHfCXGlUSU6JRWK=
CESS MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[2dGZtUUN3ME2xN{4yOyCwTR?= M2jWS3NCVkeHUh?=
KE-37 NYP1TXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDuO4xSUUN3ME2xOk4xPyCwTR?= MX;TRW5ITVJ?
SK-UT-1 M3TKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF4LkixJI5O M4CzS3NCVkeHUh?=
SIG-M5 NH3XemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwR256UUN3ME2xO{4zPSCwTR?= MmGwV2FPT0WU
HT M3:2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X3dmlEPTB;MUeuOkBvVQ>? NHnXW4FUSU6JRWK=
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGntOlVKSzVyPUG3Mlk6KG6P M2CxRXNCVkeHUh?=
SK-PN-DW M3jseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnl[lBKSzVyPUKwMlI{KG6P MUfTRW5ITVJ?
RPMI-8402 NYL2UVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDIVY1KSzVyPUKxMlc4KG6P NW\zVod7W0GQR1XS
RPMI-6666 NXXjd3ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC2TWM2OD1{ND60NkBvVQ>? MojWV2FPT0WU
NCI-H720 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr1PWxKSzVyPUK1MlQyKG6P MX\TRW5ITVJ?
EW-16 NEDyNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;N[mlEPTB;Mk[uPFchdk1? Mni4V2FPT0WU
BL-70 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHHeHd4UUN3ME2yPE4{QCCwTR?= MnLEV2FPT0WU
SF126 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjXc5hKSzVyPUOwMlM5KG6P NHOyUGdUSU6JRWK=
BC-1 NUHmb4c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fPO2lEPTB;M{GuNlYhdk1? NIe4[2xUSU6JRWK=
MHH-PREB-1 NES3Ro9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTN{LkS0JI5O NYf2OlAzW0GQR1XS
A101D MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELEcJhKSzVyPUOyMlYzKG6P M2jIcnNCVkeHUh?=
NMC-G1 MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm5SlQ5UUN3ME2zN{43PyCwTR?= Mlq1V2FPT0WU
LB1047-RCC M1zm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTmTWM2OD1|ND62PUBvVQ>? MWnTRW5ITVJ?
EM-2 M3XveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\4OGlEPTB;M{iuOVMhdk1? MkDaV2FPT0WU
COLO-684 M2PCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDxSoJnUUN3ME2zPU45KG6P NI\xRXpUSU6JRWK=
Becker MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\Ne21KSzVyPUSxMlA2KG6P NFrsbJVUSU6JRWK=
BL-41 NFG3ZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW3OmhKSzVyPUSzMlY3KG6P MkXCV2FPT0WU
MDA-MB-134-VI NEL3fJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjJWHNxUUN3ME20OE4xOiCwTR?= Mn:yV2FPT0WU
L-363 NHiybXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rnb2lEPTB;NESuO|Mhdk1? NGr2TIpUSU6JRWK=
ECC4 NEXUN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK0TWM2OD12ND63PEBvVQ>? NYPpWVg5W0GQR1XS
A388 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17qUGlEPTB;NESuPFIhdk1? MmHOV2FPT0WU
HEL M4PYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGwcmVNUUN3ME20PU44QSCwTR?= MVjTRW5ITVJ?
RKO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\4TWM2OD13MD6yPUBvVQ>? MVHTRW5ITVJ?
KINGS-1 M1XKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDFTWM2OD13MT61OUBvVQ>? Ml3zV2FPT0WU
EB-3 M{ntR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPjTWM2OD13Mj62O{BvVQ>? MXPTRW5ITVJ?
ARH-77 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXzb41KSzVyPUWyMlghdk1? M1T5fnNCVkeHUh?=
GCIY MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTV|LkS2JI5O MlXBV2FPT0WU
NCI-H1304 NYDBXHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYUGhNUUN3ME21O{4zOiCwTR?= MVPTRW5ITVJ?
KARPAS-299 MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnEZol2UUN3ME22NU45OiCwTR?= M2\Jc3NCVkeHUh?=
IA-LM M3\ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLu[HhIUUN3ME22PE4yOyCwTR?= NFTDTHRUSU6JRWK=
GI-1 NVG5PVZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXzcHhxUUN3ME23NE4{QSCwTR?= MluxV2FPT0WU
TE-11 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTd5LkG3JI5O NUjT[Wl2W0GQR1XS
LS-411N NYXaRW03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\UNYdKSzVyPUe3MlU4KG6P NEiySphUSU6JRWK=
no-11 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP2UGZKSzVyPUizMlI1KG6P NEGwbHpUSU6JRWK=
MV-4-11 M325bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnNdpBxUUN3ME24N{44OyCwTR?= MYLTRW5ITVJ?
BV-173 M2rTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPqS2pKSzVyPUizMlk4KG6P MXrTRW5ITVJ?
CMK NXv5c4lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m5T2lEPTB;OESuNVYhdk1? MYHTRW5ITVJ?
LC4-1 NVLsbJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK5TWM2OD16Nj63NkBvVQ>? NW\veGFMW0GQR1XS
COR-L279 M1rI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTh5LkK1JI5O M3fpbHNCVkeHUh?=
NCI-H209 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS0SIFTUUN3ME24O{41OSCwTR?= MXPTRW5ITVJ?
Raji MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTh7LkeyJI5O NFn1OnBUSU6JRWK=
LB996-RCC M1jXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHCPVRKSzVyPUmzMlQ{KG6P MVLTRW5ITVJ?
NCI-H526 NH;vWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTl|LkW5JI5O MonNV2FPT0WU
KGN M3rlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToTWM2OD17Nj6yPUBvVQ>? MmXnV2FPT0WU
MOLT-4 MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonnTWM2OD17Nj63PUBvVQ>? NUXEUmxYW0GQR1XS
PF-382 NYXm[XdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTl4Lke5JI5O MUTTRW5ITVJ?
BC-3 NE\3e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfIRWZKSzVyPUm5MlE5KG6P MUfTRW5ITVJ?
KARPAS-422 M2X5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFyMj6wPUBvVQ>? M2rJWHNCVkeHUh?=
SBC-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHNS3FKSzVyPUGwO{44PSCwTR?= NXvU[|JCW0GQR1XS
LC-1F Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPGVYJoUUN3ME2xNFgvODVibl2= M174SnNCVkeHUh?=
GB-1 NIPnSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyOT6wNkBvVQ>? NXLQUodKW0GQR1XS
SNB75 M3TjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFzOT62PUBvVQ>? NF;nSodUSU6JRWK=
BB65-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTLTWM2OD1zMUmuPVMhdk1? M4LhfnNCVkeHUh?=
NCI-N87 NFexdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLjOZFnUUN3ME2xNlEvQThibl2= MWrTRW5ITVJ?
IST-MEL1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF{Mj6zPEBvVQ>? NGDUb21USU6JRWK=
HOP-62 M1zsOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3aTWM2OD1zMk[uPFkhdk1? Mn7TV2FPT0WU
ACN NH;VUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDD[ZNRUUN3ME2xOFYvPzVibl2= MVTTRW5ITVJ?
DMS-114 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W1XmlEPTB;MUWwMlY4KG6P M1PSXnNCVkeHUh?=
MLMA NGKycFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF3OT64PEBvVQ>? MnPpV2FPT0WU
HT-144 NGjnb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;iNGlEPTB;MU[1MlQ{KG6P M{nvc3NCVkeHUh?=
C2BBe1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXBTWM2OD1zNkeuO|Yhdk1? NHvwUmxUSU6JRWK=
L-428 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTVTWM2OD1zN{euO{BvVQ>? NUTQTpRsW0GQR1XS
DU-4475 NWPQd|ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF6Nz62PEBvVQ>? MoPqV2FPT0WU
CP67-MEL MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTXTWM2OD1zOUmuN|ghdk1? MnfwV2FPT0WU
MEG-01 M4fvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJyMT65OkBvVQ>? M2LROnNCVkeHUh?=
IST-SL2 NWPMUWxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX20XINiUUN3ME2yNFgvPjNibl2= M2TubnNCVkeHUh?=
ES8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJ{NT65OEBvVQ>? MkHOV2FPT0WU
COLO-800 M2GxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJ|NT6yPEBvVQ>? M3zMdnNCVkeHUh?=
MFH-ino NFrMeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPZZdKSzVyPUKzOU45PCCwTR?= Mn;vV2FPT0WU
OVCAR-4 NEPsSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7LTWM2OD1{M{euNlQhdk1? NHLkN4RUSU6JRWK=
PSN1 NHrDeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ2Mj63NUBvVQ>? M3PT[HNCVkeHUh?=
EW-12 M1Ly[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TJU2lEPTB;MkSzMlEhdk1? NG[3Wm5USU6JRWK=
HCC1599 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ4MT60O{BvVQ>? NX65XHB2W0GQR1XS
SJSA-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzVe2dKSzVyPUK3NU41PiCwTR?= NYexV29xW0GQR1XS
ST486 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2b2lEPTB;Mkm2MlE1KG6P NH;HPGhUSU6JRWK=
NOMO-1 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTNyMD6yNUBvVQ>? MmTQV2FPT0WU
MN-60 M2m0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnGUVZHUUN3ME2zNFUvOzJibl2= MnXiV2FPT0WU
HCC1187 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNyNz6yOUBvVQ>? MljkV2FPT0WU
SW982 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;QUJdYUUN3ME2zNVQvPzVibl2= MYTTRW5ITVJ?
LB647-SCLC Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3JeXZDUUN3ME2zNlgvPzFibl2= M4XJbHNCVkeHUh?=
HC-1 NGHxdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO2TWM2OD1|M{WuOUBvVQ>? MYnTRW5ITVJ?
EHEB M1;GN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LnVWlEPTB;M{O3MlUzKG6P MmDrV2FPT0WU
TUR NGrHPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH4TWM2OD1|NkOuPVUhdk1? MV3TRW5ITVJ?
LU-139 NELyU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTFclRnUUN3ME2zO|gvODJibl2= NFXzZ4tUSU6JRWK=
NB1 NYPHZ2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\CZ5FxUUN3ME2zPFQvPDVibl2= MkTBV2FPT0WU
BB30-HNC NF7UNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LTbWlEPTB;M{i4MlMzKG6P MkH4V2FPT0WU
HAL-01 NEP1[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDTTWM2OD1|OEmuNlYhdk1? NYnlV5VVW0GQR1XS
K5 NYDNTYR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3tfVBKSzVyPUSxNU4{PyCwTR?= NGXzbWZUSU6JRWK=
MZ2-MEL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCxOlVKSzVyPUSxN{43PCCwTR?= NXvNNoZ1W0GQR1XS
RXF393 NEf6XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nkcWlEPTB;NEG2MlQ2KG6P MXvTRW5ITVJ?
NCI-H1648 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDmcmZKSzVyPUSxO{42OyCwTR?= M1WxbHNCVkeHUh?=
TE-12 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHYTWM2OD12M{SuNlYhdk1? NFTyZolUSU6JRWK=
EoL-1- MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Ll[mlEPTB;NEO3Mlk5KG6P M{jrfnNCVkeHUh?=
JAR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD5TWM2OD12M{iuOlIhdk1? NIrXdY9USU6JRWK=
DSH1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTR3OD65NUBvVQ>? NWjyXWw3W0GQR1XS
NCI-H187 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv6VFdKSzVyPUS2Nk45OSCwTR?= MUfTRW5ITVJ?
HCE-4 NHr4PXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC5fJIyUUN3ME20O|cvPjZibl2= MkS4V2FPT0WU
8-MG-BA NVHC[|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTV6MT61NkBvVQ>? NYnN[mVXW0GQR1XS
KLE M2jWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzWWZRWUUN3ME21PFUvOiCwTR?= MonSV2FPT0WU
KNS-42 M4jWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTV6Nj64NUBvVQ>? NYntdG5OW0GQR1XS
MSTO-211H M3fKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XoUWlEPTB;NkC5Mlc1KG6P NG\KSZRUSU6JRWK=
GDM-1 NUXXcIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DhTGlEPTB;NkG0MlA6KG6P MoC4V2FPT0WU
TE-1 NHLXXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXrUFN2UUN3ME22OFYvOTJibl2= NEnvclZUSU6JRWK=
BT-474 M1HRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfwTWM2OD14NEeuNFYhdk1? M4nG[3NCVkeHUh?=
KARPAS-45 NXPsZ3ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZ2Nz62JI5O MWPTRW5ITVJ?
MOLT-16 M4DTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv3[pVKSzVyPU[0O{46OyCwTR?= NEK3b|BUSU6JRWK=
KURAMOCHI MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrVHNMUUN3ME22OVcvPTFibl2= MV7TRW5ITVJ?
K-562 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXpe5lKSzVyPU[2PU42OSCwTR?= M{LE[nNCVkeHUh?=
EKVX NG\zdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjqTWM2OD14N{KuO|Ehdk1? MULTRW5ITVJ?
GAK NFW2WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTZ5NT6zJI5O M1O1bXNCVkeHUh?=
NCI-SNU-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULwfZhjUUN3ME22PVAvODFibl2= NFrWXGxUSU6JRWK=
NCI-H2126 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfqTWM2OD15Mk[uPFchdk1? M2XTfXNCVkeHUh?=
CTV-1 NFW0[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK2SXdKSzVyPUe0OE46KG6P NXHDUHB4W0GQR1XS
SW962 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DQOmlEPTB;N{S4MlQ1KG6P MWTTRW5ITVJ?
MONO-MAC-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTwfXdXUUN3ME23OVYvQTNibl2= Mkm4V2FPT0WU
NCI-H748 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnrTWM2OD15NUiuPVkhdk1? M1vpW3NCVkeHUh?=
NCI-H524 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvoTWM2OD15OECuO|Mhdk1? MWnTRW5ITVJ?
LS-123 M4PKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OzUmlEPTB;N{m1MlY6KG6P MWHTRW5ITVJ?
NB7 M4KwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS2TWM2OD16MUSuNVQhdk1? M3nufXNCVkeHUh?=
LS-1034 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\STWM2OD16MkiuPVghdk1? NUj6ZYR[W0GQR1XS
TE-5 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rPZmlEPTB;OEizMlU3KG6P MYLTRW5ITVJ?
A704 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTh7OT6xOUBvVQ>? MnPsV2FPT0WU
TK10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTlzNj6wN{BvVQ>? NIjvSm5USU6JRWK=
NCI-H345 NHzSd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXP2SHU2UUN3ME25OFMvOjJibl2= MnT6V2FPT0WU
CGTH-W-1 M1e0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP1TWM2OD17NEiuNVMhdk1? NFz0T5RUSU6JRWK=
NCI-H510A Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjzTWM2OD17OEWuNVIhdk1? NH3kc3JUSU6JRWK=
NCI-H1963 NHTWVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ZTWM2OD1zLkCzNlkzKM7:TR?= MlW2V2FPT0WU
SCC-3 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3OTWM2OD1zLkCzOFE1KM7:TR?= MX7TRW5ITVJ?
EW-11 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjnOIJPUUN3ME2xMlA5PzR|IN88US=> NWTGO2dMW0GQR1XS
CPC-N MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17JU2lEPTB;MT6wPFgh|ryP NXPabFExW0GQR1XS
NCI-H1417 Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvvdmVVUUN3ME2xMlEzOjZizszN NWmwSJh1W0GQR1XS
DG-75 NE\odZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWV2dKSzVyPUGuNVYzQDVizszN MYjTRW5ITVJ?
HD-MY-Z M1K0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LzZWlEPTB;MT6xOlQyPiEQvF2= M2qzNHNCVkeHUh?=
ATN-1 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwMk[yNFkh|ryP M3nmOHNCVkeHUh?=
KM-H2 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[2dY5FUUN3ME2xMlI3PDB6IN88US=> NUPYO2FYW0GQR1XS
NCI-H2081 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwMk[2N|ch|ryP NH;xbY1USU6JRWK=
HL-60 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwMk[5OVkh|ryP MVzTRW5ITVJ?
DB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwMkeyOFIh|ryP MkTmV2FPT0WU
NCI-H1522 NYfMboFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwMki4PFch|ryP MmCwV2FPT0WU
AM-38 NVnJ[YJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzCTWM2OD1zLkOwO|Ih|ryP MYfTRW5ITVJ?
NCI-H446 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrCTGdKSzVyPUGuN|IyOjFizszN NFXoVZpUSU6JRWK=
SU-DHL-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LUUWlEPTB;MT6zNlgxOSEQvF2= NVnkfnVtW0GQR1XS
NH-12 M1nRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrnWIZHUUN3ME2xMlM3Ozd2IN88US=> M{P4UnNCVkeHUh?=
DMS-79 NYThfXpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYSwS4Q2UUN3ME2xMlM3QDZ4IN88US=> MnK2V2FPT0WU
NCI-H716 MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7uVW5KSzVyPUGuN|g6QDZizszN NXTnWGdWW0GQR1XS
ML-2 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLRTWM2OD1zLkSxOVI6KM7:TR?= NGr6cGNUSU6JRWK=
NB10 M{TBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vhTWlEPTB;MT60OlY{OiEQvF2= MnT0V2FPT0WU
ONS-76 MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn6T|VKSzVyPUGuOVM2PjlizszN M{TpUXNCVkeHUh?=
LOUCY NIXne3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojSTWM2OD1zLkW0OlU4KM7:TR?= NVnJdlQ6W0GQR1XS
SCLC-21H NUjUUmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwNUi1PFIh|ryP M4fZOXNCVkeHUh?=
TGW MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTkN5ZKSzVyPUGuOlM6PzVizszN MWPTRW5ITVJ?
LXF-289 NWKweVZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HnV2lEPTB;MT63N|I3QCEQvF2= NHPQPGhUSU6JRWK=
BB49-HNC NUi3VWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwN{O1PFYh|ryP MkX0V2FPT0WU
NCI-H747 Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHqTWM2OD1zLke1N|Q3KM7:TR?= NFnwcYZUSU6JRWK=
LU-165 NHnoOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfyTWM2OD1zLki0PVg3KM7:TR?= MkHsV2FPT0WU
OMC-1 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICz[XBKSzVyPUGuPVUxPjZizszN M{T3PXNCVkeHUh?=
RCC10RGB NEDVWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6wTWM2OD1zLkm1PFE4KM7:TR?= MX7TRW5ITVJ?
SW684 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nlR2lEPTB;MT65OlA6QSEQvF2= NIX4WmlUSU6JRWK=
TE-8 NFrQW4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW1TWM2OD1{LkC1OVU6KM7:TR?= M2fpUnNCVkeHUh?=
SK-N-DZ NFjVOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJwMUOyO|Qh|ryP MWnTRW5ITVJ?
EVSA-T M4SydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr5e3JIUUN3ME2yMlE4OzF3IN88US=> NYfhRZl3W0GQR1XS
KASUMI-1 M1juVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwMUi4NVUh|ryP MWjTRW5ITVJ?
NKM-1 M4HqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPqR|NKSzVyPUKuNlU1PzJizszN M1XJUnNCVkeHUh?=
CAL-148 NGnIRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnqdWpNUUN3ME2yMlM{PjF2IN88US=> NVK4b3dYW0GQR1XS
NCI-H64 M1r6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwM{SyN|Ih|ryP MlGzV2FPT0WU
KNS-81-FD NVqwNVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITvfVBKSzVyPUKuN|Y3OiEQvF2= MVfTRW5ITVJ?
KM12 NVXDVZc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF64dodKSzVyPUKuOFA5OzlizszN MXjTRW5ITVJ?
SW954 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LV[WlEPTB;Mj60O|c4QSEQvF2= MWTTRW5ITVJ?
NCI-H1395 NFOwc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXX[Y9KSzVyPUKuOVI3PDVizszN NUnUOnRjW0GQR1XS
DJM-1 NYjsXW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\JO41KSzVyPUKuOlA3OyEQvF2= NXvFWWZLW0GQR1XS
COLO-668 M37CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nhTGlEPTB;Mj64NlY6PSEQvF2= M13jZ3NCVkeHUh?=
NCI-H1436 NHKxRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrYS4ZpUUN3ME2yMlg2PjF3IN88US=> NYD3[ph2W0GQR1XS
LB2241-RCC M{iwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJwOE[4N|kh|ryP M4PDd3NCVkeHUh?=
GT3TKB Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[wbWlEPTB;Mj64PVA2PSEQvF2= NXzwPGw6W0GQR1XS
COLO-824 NYD4dFB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDLfIVKSzVyPUKuPFk4PjhizszN NEPHPIpUSU6JRWK=
ES1 NUDL[JJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXMNpFJUUN3ME2yMlg6QDd7IN88US=> NX7v[pdDW0GQR1XS
LB771-HNC M3TRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwOUC5OFYh|ryP M4q5TXNCVkeHUh?=
GI-ME-N MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHWUI5KSzVyPUOuNFA6ODRizszN NFLDU45USU6JRWK=
NALM-6 NIrGe2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHldG1[UUN3ME2zMlAxQTN|IN88US=> NIfOR45USU6JRWK=
LU-134-A NIDSe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXDTWM2OD1|LkC1OFI2KM7:TR?= NWfUZmJ7W0GQR1XS
DMS-153 NICxeYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX3TWM2OD1|LkC1PFI1KM7:TR?= MkDDV2FPT0WU
MZ1-PC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljhTWM2OD1|LkC5NFc5KM7:TR?= M4TndnNCVkeHUh?=
NCI-H1155 NUnVUYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwMUG2NUDPxE1? MYLTRW5ITVJ?
CAS-1 NHrGfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfifo1KSzVyPUOuNVM4ODdizszN NHvsPJJUSU6JRWK=
D-502MG M3XsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HkdmlEPTB;Mz6xOFM6KM7:TR?= NF\zUJdUSU6JRWK=
NCI-H2141 NX\rXWx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPnTWM2OD1|LkG3OFUzKM7:TR?= NXvFfmFzW0GQR1XS
NB6 NVvielA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n5WmlEPTB;Mz6xPFI2QSEQvF2= NXjDbWZOW0GQR1XS
NCCIT NVz3WXI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT5O3V{UUN3ME2zMlIyQDB7IN88US=> NFzq[ZpUSU6JRWK=
NB69 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXDO5RKSzVyPUOuN|E5QTFizszN MWjTRW5ITVJ?
JVM-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrS[JRKSzVyPUOuN|Y1OzNizszN MV;TRW5ITVJ?
K052 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{SzOWlEPTB;Mz6zO|k3QCEQvF2= MV;TRW5ITVJ?
HCC2157 M1nZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNwNUOyNlgh|ryP MYDTRW5ITVJ?
KMOE-2 NX72UHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn3RpNIUUN3ME2zMlU1OjR{IN88US=> M{fEVnNCVkeHUh?=
SF268 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj5elBlUUN3ME2zMlcyPTV2IN88US=> NYHTOWJxW0GQR1XS
CHP-126 NHnuZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfKTWM2OD1|Lke2OFU5KM7:TR?= NIDQOI9USU6JRWK=
CP66-MEL MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX6PY5KSzVyPUOuO|kxQTRizszN MmriV2FPT0WU
NCI-H69 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwMEG5N|Yh|ryP NU\BXpNZW0GQR1XS
A253 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G5T2lEPTB;ND6wNlExOSEQvF2= M1:2[XNCVkeHUh?=
NB14 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwMUC0O|kh|ryP MV7TRW5ITVJ?
NCI-H1694 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTRwMUOxNVIh|ryP MXzTRW5ITVJ?
NCI-H2196 NWfWXHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LnTmlEPTB;ND6xO|E3QSEQvF2= Mm\HV2FPT0WU
TE-9 NFfqe3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLuPGpKSzVyPUSuNVc2QDJizszN M3nLenNCVkeHUh?=
D-283MED Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRwMUi4OEDPxE1? NUfwTVhsW0GQR1XS
OCI-AML2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTOPWJKSzVyPUSuNVk1QDlizszN NWjCTJFlW0GQR1XS
D-263MG NEnKTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnhTIg5UUN3ME20MlIzQTZzIN88US=> Mnu4V2FPT0WU
MPP-89 NWKyOHBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1izcGlEPTB;ND6yO|MxPCEQvF2= M3nuOnNCVkeHUh?=
LAMA-84 NUDRdWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrYOllKSzVyPUSuN|A1OjFizszN NEfMUodUSU6JRWK=
LB373-MEL-D NHHzOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m5VWlEPTB;ND6zOlc5QSEQvF2= MlTqV2FPT0WU
UACC-257 NFL5eHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXH[G54UUN3ME20MlM6PTN2IN88US=> MmjJV2FPT0WU
MC-CAR M1LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH4TWM2OD12LkSzPVkh|ryP NXHkUllXW0GQR1XS
COLO-320-HSR MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTRwNES0Nlch|ryP NXrpd3Z7W0GQR1XS
P30-OHK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHHc|RKSzVyPUSuOlY2QDFizszN MXXTRW5ITVJ?
UACC-812 M2\JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjvTWM2OD12Lk[5NVYyKM7:TR?= NU\LU|NTW0GQR1XS
CTB-1 M2C5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPkfHlKSzVyPUSuO|E2PTVizszN MnfGV2FPT0WU
ALL-PO NU\5TYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfGcop{UUN3ME20Mlg1ODd5IN88US=> NXPkWodLW0GQR1XS
SK-MEL-2 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXFPW1QUUN3ME20Mlg3QTV3IN88US=> M2XuPHNCVkeHUh?=
TC-YIK NYHJfnpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfVT21xUUN3ME20Mlk4QTR{IN88US=> MkTHV2FPT0WU
NCI-H1882 NVnoeppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwMEKwNFEh|ryP MXHTRW5ITVJ?
MHH-CALL-2 NIeyeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHKb4lZUUN3ME21MlA2ODR{IN88US=> NYW1T|FoW0GQR1XS
U-87-MG NHyw[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzSTWM2OD13LkC5OFY3KM7:TR?= NVXuV4VWW0GQR1XS
NCI-H1092 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTVwMk[1OVUh|ryP M3HU[nNCVkeHUh?=
TE-441-T MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PPOWlEPTB;NT6yO|gzKM7:TR?= M{HKZXNCVkeHUh?=
SK-MEL-1 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrDTWM2OD13LkK5NFQ1KM7:TR?= M3z4bHNCVkeHUh?=
EW-22 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTVwMkm0OlYh|ryP NUnsOXBPW0GQR1XS
MZ7-mel NXPmXpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHMdGlKSzVyPUWuOFA3QTFizszN NHjUSJhUSU6JRWK=
LP-1 NIjkO|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX6TWM2OD13LkSxNlkyKM7:TR?= M3zvUHNCVkeHUh?=
NCI-SNU-16 NI\6[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XjU2lEPTB;NT62OFA4PCEQvF2= NGD0TlZUSU6JRWK=
LU-65 NXvndJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTVwN{[zO|Mh|ryP MV\TRW5ITVJ?
CW-2 NFnQeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO5TWM2OD13Lki1PVU6KM7:TR?= NWLlWVFyW0GQR1XS
WSU-NHL MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzcmJKSzVyPUWuPVUyPzRizszN M2XGPXNCVkeHUh?=
IST-MES1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTVwOUW0OFMh|ryP NV3SXnA1W0GQR1XS
U-266 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXnU3F[UUN3ME21Mlk5OjB{IN88US=> MnPVV2FPT0WU
TALL-1 NEDtSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwMUS2PFgh|ryP NWnWN5JiW0GQR1XS
Calu-6 M1\4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLsTWM2OD14LkG1N|E3KM7:TR?= MnzFV2FPT0WU
MMAC-SF NF25elhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r1VGlEPTB;Nj6xPFU2PiEQvF2= NWjicnJtW0GQR1XS
NCI-H82 NHXOOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjUOo9zUUN3ME22MlIxPDh7IN88US=> MlzFV2FPT0WU
RS4-11 M1zpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XCZ2lEPTB;Nj6yOVg6PyEQvF2= NHKzeGZUSU6JRWK=
SNU-C2B MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknVTWM2OD14LkSwPVY6KM7:TR?= M{S4PHNCVkeHUh?=
BOKU NHfZU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjOdIRHUUN3ME22MlQ4PTl5IN88US=> NYP0NIJrW0GQR1XS
C8166 NFTLZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfsfm9KSzVyPU[uOVU6OTJizszN NF;IOIpUSU6JRWK=
D-247MG Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MornTWM2OD15LkC0N|Q4KM7:TR?= MY\TRW5ITVJ?
EW-18 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DjWWlEPTB;Nz6wO|I6OiEQvF2= M3TBdXNCVkeHUh?=
KG-1 M4jNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPDSIVKSzVyPUeuOlI4OzhizszN NUXx[GxyW0GQR1XS
REH NWWyb5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInUXYFKSzVyPUeuOlgyODlizszN M3jaVHNCVkeHUh?=
U-698-M M2jDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPQTWM2OD15Lki0N|E2KM7:TR?= M{Hu[nNCVkeHUh?=
KP-N-RT-BM-1 NHvaTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jMZWlEPTB;Nz65N|AzQSEQvF2= Mm\6V2FPT0WU
MS-1 NGnBT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHy[WxKSzVyPUeuPVYxPDFizszN M2TMdXNCVkeHUh?=
SNU-C1 M2TLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTdwOUixPVIh|ryP NF7X[5VUSU6JRWK=
SK-MM-2 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LI[2lEPTB;OD6yOlA3PSEQvF2= M1LKVnNCVkeHUh?=
LAN-6 M{jSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jaVGlEPTB;OD6zNFAxOSEQvF2= MVfTRW5ITVJ?
NEC8 M2\3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jVXGlEPTB;OD6zNFY6OSEQvF2= NFvRfIRUSU6JRWK=
NCI-H1770 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjtVpFKSzVyPUiuN|gxODJizszN MVLTRW5ITVJ?
D-336MG NFHTRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2np[WlEPTB;OD60NFEyPiEQvF2= MkPHV2FPT0WU
COLO-829 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3roUWlEPTB;OD60PFg4QSEQvF2= MUjTRW5ITVJ?
LS-513 M1iwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;DcpNEUUN3ME24MlU6PTl7IN88US=> MnzUV2FPT0WU
YT M3rsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XxXGlEPTB;OD62NlQzPyEQvF2= M1;hbXNCVkeHUh?=
EW-24 Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HyS2lEPTB;OD63OlU1KM7:TR?= MWrTRW5ITVJ?
IST-SL1 NV7ZZ5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXTTWM2OD16Lki2OVQ{KM7:TR?= MnT0V2FPT0WU
CA46 M4\jZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknpTWM2OD16Lkm1NFk5KM7:TR?= NV;6coN{W0GQR1XS
NCI-H1838 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TTemlEPTB;OD65PFYxOiEQvF2= M{i1V3NCVkeHUh?=
NCI-H719 NIW4cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHuZ2JpUUN3ME25MlI2Ojd7IN88US=> MVvTRW5ITVJ?
HCE-T M1vhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG1bIhKSzVyPUmuN|A5PTFizszN M{PEb3NCVkeHUh?=
A498 NFX3dHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTyTWM2OD17LkO2NVI1KM7:TR?= NHyweWNUSU6JRWK=
LB831-BLC NVLKVJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTlwN{[1NlEh|ryP MXPTRW5ITVJ?
SKM-1 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTlwOEW5OlMh|ryP NXHPfYdbW0GQR1XS
THP-1 NVnUV2NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPc2dGUUN3ME25Mlk3QTF6IN88US=> M3TRfXNCVkeHUh?=
SHP-77 NF3VS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV60VIl[UUN3ME2xNE41ODdizszN MoD2V2FPT0WU
EW-3 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjMSJBKSzVyPUGwMlYzQDlizszN NGHDPIVUSU6JRWK=
KY821 NWfmemY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjEXlFHUUN3ME2xNE44PjNizszN MWjTRW5ITVJ?
NCI-SNU-1 M{Dpbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO1cpRSUUN3ME2xNU4xOjF5IN88US=> M1jqOHNCVkeHUh?=
HCC2218 NV;1cYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFzLkO5PFYh|ryP NWLjdmNUW0GQR1XS
IM-9 M{jSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKxcFhKSzVyPUGxMlUyODZizszN MlfOV2FPT0WU
NCI-H889 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLMTWM2OD1zMT61N|E{KM7:TR?= NFT4TGtUSU6JRWK=
HDLM-2 M{K4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2zTWM2OD1zMj60NVU6KM7:TR?= MnruV2FPT0WU
LB2518-MEL M2r1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPOTWM2OD1zMj62PFE2KM7:TR?= NF;Yd2xUSU6JRWK=
NCI-H23 NXXrPHRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7VTWM2OD1zMz6yOFI2KM7:TR?= MV7TRW5ITVJ?
NB17 NGHOeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S5W2lEPTB;MUOuOFU4QSEQvF2= MkK5V2FPT0WU
NCI-H322M M3Sycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF2LkSwOlgh|ryP MnvOV2FPT0WU
SUP-T1 NYXBRlVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPhNo5KSzVyPUG0MlQyOyEQvF2= NE\KfXdUSU6JRWK=
ES3 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\yZWlEPTB;MUWuNFcxOyEQvF2= M3fwdHNCVkeHUh?=
ES5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF3LkC3PFch|ryP MYjTRW5ITVJ?
NCI-H1650 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KzRWlEPTB;MUWuOFk4QSEQvF2= M32zOHNCVkeHUh?=
NCI-H226 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSxTWM2OD1zNT64O|Y5KM7:TR?= NVrMOpM1W0GQR1XS
COR-L88 M2nvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF4LkOxOEDPxE1? NGXkN|RUSU6JRWK=
SCC-15 NGLWdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;jNWlEPTB;MU[uN|g3QSEQvF2= M3;LW3NCVkeHUh?=
GOTO Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjoTWM2OD1zNj60O|k{KM7:TR?= M1zpSnNCVkeHUh?=
SIMA NGXkbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3DTWM2OD1zNj60PFAzKM7:TR?= NYf1eVZmW0GQR1XS
NCI-H1299 M2nQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF5LkG1PVEh|ryP M2H6NHNCVkeHUh?=
NCI-H1581 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITMelRKSzVyPUG3MlQzOTlizszN NGjpZZVUSU6JRWK=
MHH-NB-11 M3K1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13wfmlEPTB;MUeuPVY5OyEQvF2= MX\TRW5ITVJ?
MFM-223 NFzOfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF6LkC1N|gh|ryP M{TuPXNCVkeHUh?=
ES7 NYe3WnA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n1UWlEPTB;MUiuOVQ{OSEQvF2= NYXidWdYW0GQR1XS
JVM-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrYSZJ6UUN3ME2xPE44OTdizszN NVzG[3RMW0GQR1XS
RL NVHmW2M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPmc21KSzVyPUKwMlM5QCEQvF2= Mn[yV2FPT0WU
EC-GI-10 NGTEd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nv[WlEPTB;MkGuNlA1OSEQvF2= M4jwbHNCVkeHUh?=
LNCaP-Clone-FGC NX30Z5M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfYOldKSzVyPUKxMlY4PjhizszN M{TmNnNCVkeHUh?=
IMR-5 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrtNY5{UUN3ME2yNU45PDl2IN88US=> MYTTRW5ITVJ?
KP-N-YS MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJzLki3OUDPxE1? MlzwV2FPT0WU
Mo-T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\1[GlEPTB;MkKuNlE5PSEQvF2= NH\aNYlUSU6JRWK=
NCI-H128 MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ|LkW4OVMh|ryP MoDFV2FPT0WU
RH-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPqSWFpUUN3ME2yN{44QDZ4IN88US=> MorSV2FPT0WU
NCI-H2171 NGP4WlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJ2LkK0PFUh|ryP NHfNVINUSU6JRWK=
RPMI-8866 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknOTWM2OD1{Nj63OFIh|ryP NH;VS21USU6JRWK=
SK-N-FI NH3LNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fFPGlEPTB;MkeuN|gyOSEQvF2= MlHQV2FPT0WU
LOXIMVI Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHPb|NKSzVyPUK3MlgxPTFizszN NX3TW3BpW0GQR1XS
P31-FUJ Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;MTWlEPTB;M{GuOVM4PCEQvF2= M171enNCVkeHUh?=
KMS-12-PE NXi5N3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR7LkWzNFIh|ryP M{TEUXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
臨床試験 A Phase II study of Rapamycin to erase angiofibromas in patients with Tuberous Sclerosis Complex (TSC) is currently ongoing.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

細胞アッセイ:

[3]

細胞株 U87-MG, T98G, and U373-MG
濃度 Dissolved in DMSO, final concentrations ~25 μM
反応時間 72 hours
実験の流れ

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

動物実験:

[7]

動物モデル Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
製剤 Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
投薬量 ~4 mg/kg/day
投与方法 Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Rapamycin (Sirolimus) SDF
分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管 3年-20℃
2年-80℃in solvent
別名 AY 22989,NSC-2260804
溶解度 (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

文献中の引用 (63)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β阻害剤で、IC50値が10 nM と6.7 nMに分かれます。

  • Dorsomorphin (Compound C, BML-275)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt阻害剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • Everolimus (RAD001)

    Everolimus (RAD001)は一種のmTOR阻害剤で、FKBP12に作用します。無細胞試験でIC50値は1.6-2.4 nMになります。

  • AZD8055

    AZD8055は一種の新たなATP競争性mTOR阻害剤で、MDA-MB-468細胞の中でIC50値は0.8 nMです。AZD8055はmTORに作用する選択性はPI3K亜型とATM/DNA-PKに作用する選択性より約1000倍が高くなります。臨床1期。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1は一種の有効なmTORC1/2阻害剤で、無細胞試験でIC50値が2 nM/10 nMになって、mTORに作用する選択性はPI3Kに作用する選択性より1000倍が高くなります。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は一種の特定なmTOR阻害剤で、無細胞試験でIC50値は1.76 μMです。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は一種の有効的で、選択性mTOR阻害剤で、無細胞試験でこのIC50値が1 nMです。INK 128 (MLN0128)はmTORに作用する効果はI型PI3K亜型に作用する効果より200倍以上が高くなります。ラパマイシン(Rapamycin)に比べて、INK 128 (MLN0128)は優先にmTORC1/2を抑制し、促侵入遺伝子( pro-invasion genes )に敏感です。臨床1期。

最近チェックしたアイテム

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ